AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
61 hedge funds and large institutions have $26.5M invested in AVEO Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.
87% more call options, than puts
Call options by funds: $2.42M | Put options by funds: $1.29M
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
3% more funds holding
Funds holding: 59 → 61 (+2)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
27% less capital invested
Capital invested by funds: $36.2M → $26.5M (-$9.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.07M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$506K |
| 3 |
BlackRock
New York
|
+$239K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$217K |
| 5 |
Two Sigma Investments
New York
|
+$75.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.67M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$523K |
| 3 |
Millennium Management
New York
|
-$159K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$119K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$83K |
AVEO Hedge Fund Activity: Q4 2019 in Review
61 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2019, worth a combined $26.5M — down 27% from $36.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AVEO positions and 12 closed out — a net gain of 3 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.07M. The largest seller was 683 Capital Management, exiting entirely with an estimated $1.67M sold.
- 61 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2019, up from 59 in Q3 2019.
- Funds reported $26.5M of AVEO Pharmaceuticals, Inc. stock for Q4 2019, down 27% quarter-over-quarter.
- 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2019 and 12 closed out, a net change of +3 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2019 was Jacobs Levy Equity Management, an estimated $1.07M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2019 was 683 Capital Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2019.